Cargando…

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

INTRODUCTION: Since current treatment options for patients suffering from active rheumatoid arthritis (RA) remain inadequate, especially for those unresponsive to disease-modifying antirheumatic drugs (DMARDs), new and improved medication is needed. This study evaluates the safety and efficacy of ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tebib, Jacques, Mariette, Xavier, Bourgeois, Pierre, Flipo, René-Marc, Gaudin, Philippe, Le Loët, Xavier, Gineste, Paul, Guy, Laurent, Mansfield, Colin D, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier, Sibilia, Jean
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714151/ https://www.ncbi.nlm.nih.gov/pubmed/19549290 http://dx.doi.org/10.1186/ar2740

Ejemplares similares

Neuroprotective effect of masitinib in rats with postischemic stroke
por: Kocic, Ivan, et al.
Publicado: (2014)

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
por: Moura, Daniela Silva, et al.
Publicado: (2011)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
por: Davidescu, Lavinia, et al.
Publicado: (2022)

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
por: Deplanque, G., et al.
Publicado: (2015)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
por: Belin-Rauscent, A., et al.
Publicado: (2018)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

More about masitinib
por: Walker, Ulrich A
Publicado: (2009)

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
por: Trias, Emiliano, et al.
Publicado: (2016)

Interaction of Masitinib with Organic Cation Transporters
por: Harrach, Saliha, et al.
Publicado: (2022)

Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study
por: Flipo, René-Marc, et al.
Publicado: (2017)

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
por: Petrov, Dmitry, et al.
Publicado: (2017)

Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
por: de Bandt, Michel, et al.
Publicado: (2009)

Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA)
por: Dougados, Maxime, et al.
Publicado: (2015)

Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study
por: Le Loët, Xavier, et al.
Publicado: (2005)

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
por: De Bandt, Michel, et al.
Publicado: (2005)

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
por: Durojaye, Olanrewaju Ayodeji, et al.
Publicado: (2023)

Infectious sacroiliitis: a retrospective, multicentre study of 39 adults
por: Hermet, Marion, et al.
Publicado: (2012)

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
por: Milovancev, Milan, et al.
Publicado: (2016)

Treatment of active rheumatoid arthritis: comparison of patients younger vs older than 75 years (CORPUS cohort)
por: Oishi, Sachiyo, et al.
Publicado: (2018)

Development of Masitinib Derivatives with Enhanced M(pro) Ligand Efficiency and Reduced Cytotoxicity
por: Menendez, Cintia A., et al.
Publicado: (2023)

Variations in the metabolome in response to disease activity of rheumatoid arthritis
por: Tatar, Zuzana, et al.
Publicado: (2016)

Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
por: Fautrel, Bruno, et al.
Publicado: (2012)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
por: Ledoux, Jean-Marie, et al.
Publicado: (2014)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis
por: Cheung, Peter P, et al.
Publicado: (2016)

Biomarkers in Rheumatoid Arthritis
por: Goëb, Vincent, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mf9glm20ds3regp8n2isrgd2n0